Eli Lilly Invests $4 Billion to Expand Vaccine Portfolio

Deep News05-26

Eli Lilly is accelerating its expansion into the infectious disease field through a series of acquisitions, bringing Curevo, LimmaTech, and another vaccine company into its fold at a total cost of approximately $4 billion. This move aims to enrich its pipeline of vaccines and anti-infective drugs, particularly candidate products for diseases such as shingles. In recent years, major pharmaceutical companies have been strengthening their vaccine businesses through mergers and acquisitions. Eli Lilly's strategic investment highlights its long-term confidence in the infectious disease prevention market in the post-pandemic era. Following the integration, Eli Lilly's research and development as well as commercialization capabilities are expected to see significant enhancement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment